Risk of relapse in leprosy after fixed-duration multidrug therapy.
Between 1986 and 1995, 8307 leprosy patients have completed fixed-duration multidrug therapy (FD-MDT) and were followed annually for possible relapse. The mean relapse rate for multibacillary (MB) leprosy is 0.15/1000 person-years (py) and for paucibacillary (PB) 0.55/1000 py. There is no difference in the relapse rates between patients with or without chemotherapy before FD-MDT. In MB patients, the five relapses occurred between 4 and 7 years; in PB patients, five relapses occurred at 4-5 years after FD-MDT. Six additional PB relapses self-reported 1-4 years after the 5-year surveillance period and were not included in the relapse rates. Most PB patients relapsed into MB due to wrong classification and insufficient therapy. For the known 62 irregular MB patients the cumulative relapse rate is 6.5%.
Li
H Y
HY
Beijing Tropical Medical Research Institute, China.
Hu
L F
LF
Huang
W B
WB
Liu
G C
GC
Yuan
L C
LC
Jin
Z
Z
Li
X
X
Li
J L
JL
Yang
Z M
ZM
D000890:Anti-Infective Agents / Q000627:therapeutic use*; D002681:China / Q000453:epidemiology; D003140:Communicable Disease Control; D004359:Drug Therapy, Combination; D006801:Humans; D007917:Leprostatic Agents / Q000627:therapeutic use*; D007918:Leprosy / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D012008:Recurrence; D012306:Risk; D014944:World Health Organization
D000890:Anti-Infective Agents; D007917:Leprostatic Agents